

Last updated: September 17, 2025

Referral for Outpatient Remdesivir for COVID-19

EMAIL COMPLETED FORM TO: ConnectedCareHub@uhn.ca or fax 416-340-4135

Referral form may not be processed if all sections are not completed.

IMPORTANT: In order to qualify for start of treatment, patients need to a) Be within 7 days of symptom onset b) Meet criteria for use c) Be able to receive three days of consecutive IV therapy in clinic (in home, by exception).

Patient Demographics & History			
Full Name:		MRN (if available):	
Date of Birth:		Patient HCN (include Version Code):	
Address:			
Phone Number:		Email:	
Allergies:		OR <input type="checkbox"/> No known allergies	
Patient has a history of serious adverse or allergic reaction to the prescribed medication or related compound?			<input type="checkbox"/> Yes <input type="checkbox"/> No
Brief medical history & current medication list (prescription, non-prescription, over the counter and herbal) <i>Where applicable, documentation with this information can be attached</i>		<input type="checkbox"/> See clinical note below (page 3) <input type="checkbox"/> Patient reviewed for drug-drug interaction	
Criteria for Use			
Date of Symptom Onset:		Date of Positive Test:	
Test Type: <input type="checkbox"/> PCR Test <input type="checkbox"/> Rapid Antigen Test <input type="checkbox"/> Rapid Molecular Test			
Prescriber acknowledges Ontario Health (OH) & MOH guidelines have been met:			<input type="checkbox"/> Yes <input type="checkbox"/> No
Please select the eligibility criteria the patient meets: (see Recommendations for Antiviral Therapy for Adults with Mild to Moderate COVID-19 for more information)			
<input type="checkbox"/> Adults ≥65 years of age with no other risk factors (regardless of vaccination status)			
<input type="checkbox"/> Immunocompromised adults ≥18 (regardless of vaccination status or prior infections). Examples: <ul style="list-style-type: none"> • active hematological malignancy or post stem cell transplant or CAR T-cell therapy in last 6 months • solid organ transplant • hypogammaglobulinemia • taking prednisone greater than 20 mg/day (or equivalent) for more than 14 days • other moderately or severely immunosuppressive therapies (example: anti-CD20 agents, alkylating agents, cancer chemotherapy) 			
<input type="checkbox"/> Adults at increased risk due to one or more medical conditions or risk factors <ul style="list-style-type: none"> • Have never received a COVID-19 vaccine • Medical Conditions (e.g. Chronic kidney, lung or liver diseases; Diabetes mellitus, type 1 or type 2; disabilities and developmental delay; Heart conditions; Mental health conditions; Obesity (body mass index above 30 kg/m²); Pregnancy or recent pregnancy) 			

Patient Demographics & History			
Full Name:		Date of Birth:	
Patient HCN (include Version Code):			
Criteria for Use (cont'd)			
Renal Function	Creatinine umol/L:		eGFR: <input type="checkbox"/> Not Available
	Please specify reason for approval: (Note: no dose adjustment required with impaired renal function, including patients on dialysis)		
Liver Function	ALT:	ALP:	Bili: Date: <input type="checkbox"/> Not Available
	INR:	Date: <input type="checkbox"/> Not Available	
Complex patient requiring consultation by ID:		<input type="checkbox"/> Yes <input type="checkbox"/> N/A	If yes, <input type="checkbox"/> See clinical note/documentation attached ID Physician Consulted:
Patient willing to travel to receive treatment (three consecutive days):			<input type="checkbox"/> Yes <input type="checkbox"/> No
For patients receiving a First Dose			
Is patient on beta-blockers?			<input type="checkbox"/> Yes <input type="checkbox"/> No
<i>Please note: as per the latest OH guidelines, there are no contraindications for patients on beta blockers and the benefit of Remdesivir treatment outweighs the risk</i>			
Remdesivir Prescription			
Remdesivir LU Code: 722			
Remdesivir Prescription (no dose adjustments required for eGFR less than 30 per advisement by Infectious Diseases physicians): <input type="checkbox"/> Remdesivir 200mg IV day 1, followed by Remdesivir 100mg IV on Day 2, & Remdesivir 100mg IV on Day 3 <input type="checkbox"/> Remdesivir 100mg IV on Day 2 and Remdesivir 100mg IV on Day 3 (day 1 already completed on: [Date & Time]) <input type="checkbox"/> IV Remdesivir:			
<i>NOTE: Administer Remdesivir per institution/clinic policy. No refills. Remdesivir must be given over three consecutive days, unless otherwise indicated.</i>			
Dose Adjustments (please note if there are any medications being held or adjusted below): Hold _____ for _____ days from starting Remdesivir <i>NOTE: This prescription is only for Remdesivir and not intended for any other medications. Please fill out a separate prescription if your patient requires additional medications</i>			
Administration Orders			
<input type="checkbox"/> Insert saline lock – discontinue after treatment is complete <input type="checkbox"/> Saline lock in place – discontinue after treatment is complete			
Prescriber Attestation			
<input type="checkbox"/> I affirm that the patient meets the above criteria for use and appropriate assessment has been completed.			
Physician/NP Name:		Phone Number:	
Email:		CPSO#:	
Physician/NP Signature:		Date:	

Patient Demographics & History	
Full Name:	Date of Birth:
Patient HCN (include Version Code):	
Remdesivir Clinical Note and Medication List	